scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1048024169 |
P356 | DOI | 10.1186/S13059-015-0657-6 |
P932 | PMC publication ID | 4440518 |
P698 | PubMed publication ID | 25994018 |
P5875 | ResearchGate publication ID | 277018168 |
P50 | author | Jorge Reis-Filho | Q23892845 |
Paul M Wilkerson | Q114430433 | ||
Patty Wai | Q114430434 | ||
Huei-Chi Wen | Q117222753 | ||
Rachael Natrajan | Q30582887 | ||
Frédérique Penault-Llorca | Q30728827 | ||
Luciano G. Martelotto | Q48118380 | ||
Charlotte K Y Ng | Q52733272 | ||
Raymond Lim | Q57152271 | ||
Britta Weigelt | Q71780641 | ||
Felipe C Geyer | Q89462283 | ||
Arnaud Gauthier | Q103831905 | ||
Larry Norton | Q37644083 | ||
Salvatore Piscuoglio | Q41195760 | ||
Anne Vincent-Salomon | Q41605826 | ||
Xavier Sastre-Garau | Q41607337 | ||
Magali Lacroix-Triki | Q41608027 | ||
P2093 | author name string | Frederique Penault-Llorca | |
Laurent Arnould | |||
Paul H Cottu | |||
Sylvia Giard | |||
Daniel N Rodrigues | |||
Catherine F Cowell | |||
Silvio E Bromberg | |||
P2860 | cites work | ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium | Q24293658 |
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice | Q24296333 | ||
Intratumor heterogeneity: evolution through space and time | Q24598678 | ||
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts | Q24621116 | ||
Comprehensive molecular portraits of human breast tumours | Q24630844 | ||
A census of human cancer genes | Q24647081 | ||
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity | Q27006811 | ||
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
Activating HER2 mutations in HER2 gene amplification negative breast cancer | Q27851987 | ||
Activating ESR1 mutations in hormone-resistant metastatic breast cancer | Q27852630 | ||
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer | Q27852637 | ||
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
RCP is a human breast cancer-promoting gene with Ras-activating function | Q28252569 | ||
Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer | Q28279694 | ||
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up | Q28306437 | ||
Tumour evolution inferred by single-cell sequencing | Q28646966 | ||
Inferring tumor progression from genomic heterogeneity | Q28749457 | ||
The life history of 21 breast cancers | Q29614642 | ||
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups | Q29614700 | ||
Fibroblast growth factor signalling: from development to cancer | Q29616827 | ||
The clonal and mutational evolution spectrum of primary triple-negative breast cancers | Q29619914 | ||
Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. | Q30459163 | ||
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer | Q30494798 | ||
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 | Q30543788 | ||
Resolving the resolution of array CGH. | Q33271882 | ||
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast | Q33579776 | ||
Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma | Q33644421 | ||
Clonal evolution in breast cancer revealed by single nucleus genome sequencing. | Q34041603 | ||
Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas | Q34094563 | ||
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer | Q34200610 | ||
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer | Q46755338 | ||
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 | ||
Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event | Q79825280 | ||
Prognosis and gene expression profiling of 20q13-amplified breast cancers | Q80087862 | ||
Insights from transgenic mouse models of ERBB2-induced breast cancer | Q80188238 | ||
Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia--a comparative study of four differently designed, high resolution microarray platforms | Q81290124 | ||
Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer | Q34216744 | ||
Absolute quantification of somatic DNA alterations in human cancer | Q34271693 | ||
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution | Q34442770 | ||
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis | Q34493341 | ||
The Mub1/Ubr2 ubiquitin ligase complex regulates the conserved Dsn1 kinetochore protein | Q34585694 | ||
Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations | Q34663070 | ||
Transforming Properties of 8p11-12 Amplified Genes in Human Breast Cancer | Q34950377 | ||
Modelling glandular epithelial cancers in three-dimensional cultures | Q36251934 | ||
Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease | Q36615272 | ||
Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity | Q36732343 | ||
Getting it right: designing microarray (and not 'microawry') comparative genomic hybridization studies for cancer research | Q36844700 | ||
Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort | Q37006537 | ||
CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer | Q37121911 | ||
Immunophenotypic and genomic characterization of papillary carcinomas of the breast | Q37130628 | ||
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection | Q37155717 | ||
Neuregulins and cancer. | Q37179990 | ||
DNA amplifications in breast cancer: genotypic-phenotypic correlations | Q37763102 | ||
Epistatic interactions and drug response | Q38150749 | ||
Biomarkers of drugs targeting HER-family signalling in cancer. | Q38150774 | ||
The genomic profile of HER2-amplified breast cancers: the influence of ER status | Q38360582 | ||
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs | Q39584693 | ||
Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer | Q39945589 | ||
eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration | Q40203753 | ||
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas | Q40205335 | ||
Comprehensive profiling of 8p11-12 amplification in breast cancer | Q40335646 | ||
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing | Q43118556 | ||
Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance | Q44838384 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P304 | page(s) | 107 | |
P577 | publication date | 2015-05-22 | |
P1433 | published in | Genome Biology | Q5533480 |
P1476 | title | Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification | |
P478 | volume | 16 |